Clinical Trial Update: Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome [Phase 3]

View source ↗

Summary

Phase 3 clinical trial completed evaluating the efficacy of botulinum toxin for scleroderma-associated Raynaud's phenomenon; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon
• Systemic Sclerosis

Drugs mentioned

• Botulinum toxin (botulinum toxin)

Snippet

Sponsor: Johns Hopkins University | Conditions: Scleroderma, Raynaud's Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2016-12-22